Infectious Disease
RSSArticles
-
An Alternating QRS with AV Block?
There is no 12-lead ECG on this patient, which means that our assessment of QRS morphology is limited to this single right-sided MCL-1 monitoring lead.
-
Clinical Briefs
In this section: connecting asthma to obesity; finding the right treatment for uncomplicated gastroesophageal reflux disease; and better blood pressure control.
-
Bezlotoxumab Injection (Zinplava)
Bezlotoxumab neutralizes the effect of toxin B and reduces the rate of recurrence of C. difficile infection.
-
Is Yoga Effective for Treating Asthma?
Although the data on yoga in asthma are only of moderate quality, they suggest that yoga may improve quality of life and asthma symptoms.
-
What Influences ICU Admission?
High ICU utilization hospitals were more likely to use invasive procedures and incurred higher costs than low ICU utilization hospitals with no difference in mortality.
-
Is Anxiety a Risk Factor for Cardiovascular Disease?
Anxiety disorders are associated with an elevated risk of a range of different cardiovascular events including stroke, coronary heart disease, heart failure, and cardiovascular deaths, but it is unclear whether these disorders are causal in nature.
-
Infectious Disease Alert Updates
Wee Bacterium Parasitizes Other Oral Bacteria; How Safe Is Your Honey?; Benefits of TB Screening Confirmed
-
Can the Human Papillomavirus Vaccine Cure Cervical Dysplasia?
In this randomized, controlled trial, the HPV 16/18 vaccine did not hasten resolution of existing oncogenic HPV infections nor prevent persistent HPV 16/18 associated infection and cervical dysplasia recurrence after loop electrosurgical excisional procedure treatment.
-
VRE and MRSA: Should We Stop Routine Contact Precautions?
The value of routine contact precautions for VRE and MRSA is strongly challenged.
-
Empirical Antifungals in the ICU — Probably Not Helpful
Two hundred sixty non-neutropenic ICU patients with clinical evidence of sepsis receiving broad-spectrum antibiotics and known to be colonized by Candida species were randomized to micafungin for 14 days vs. placebo. Empirical micafungin therapy did not increase invasive fungal infection-free survival at 28 days.